In further concordance, an association has been reported between high SRC-3 levels and poor outcomes in multiple myeloma patients treated with bortezomib, which suggests that targeting SRC-3 may be a promising approach to help overcome drug resistance [152]. This evidence concerns the gene NCOA3 and AL amyloidosis.